Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2

Neurology. 2018 Jun 5;90(23):e2059-e2067. doi: 10.1212/WNL.0000000000005660. Epub 2018 May 11.

Abstract

Objective: To delineate the natural history, diagnosis, and treatment response of Parkinson disease (PD) in individuals with 22q11.2 deletion syndrome (22q11.2DS), and to determine if these patients differ from those with idiopathic PD.

Methods: In this international observational study, we characterized the clinical and neuroimaging features of 45 individuals with 22q11.2DS and PD (mean follow-up 7.5 ± 4.1 years).

Results: 22q11.2DS PD had a typical male excess (32 male, 71.1%), presentation and progression of hallmark motor symptoms, reduced striatal dopamine transporter binding with molecular imaging, and initial positive response to levodopa (93.3%). Mean age at motor symptom onset was relatively young (39.5 ± 8.5 years); 71.4% of cases had early-onset PD (<45 years). Despite having a similar age at onset, the diagnosis of PD was delayed in patients with a history of antipsychotic treatment compared with antipsychotic-naive patients (median 5 vs 1 year, p = 0.001). Preexisting psychotic disorders (24.5%) and mood or anxiety disorders (31.1%) were common, as were early dystonia (19.4%) and a history of seizures (33.3%).

Conclusions: Major clinical characteristics and response to standard treatments appear comparable in 22q11.2DS-associated PD to those in idiopathic PD, although the average age at onset is earlier. Importantly, treatment of preexisting psychotic illness may delay diagnosis of PD in 22q11.DS patients. An index of suspicion and vigilance for complex comorbidity may assist in identifying patients to prioritize for genetic testing.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antiparkinson Agents / therapeutic use
  • Databases, Bibliographic / statistics & numerical data
  • Deep Brain Stimulation
  • DiGeorge Syndrome / complications*
  • DiGeorge Syndrome / diagnosis*
  • DiGeorge Syndrome / mortality
  • DiGeorge Syndrome / therapy
  • Female
  • Humans
  • International Cooperation
  • Male
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / mortality
  • Parkinson Disease / therapy
  • Severity of Illness Index
  • Sex Distribution
  • Statistics, Nonparametric
  • Tetrabenazine / analogs & derivatives
  • Tetrabenazine / metabolism
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Antiparkinson Agents
  • dihydrotetrabenazine
  • Tetrabenazine